Compare NYC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYC | GRDX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 28.6M |
| IPO Year | 2014 | N/A |
| Metric | NYC | GRDX |
|---|---|---|
| Price | $8.52 | $6.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.1K | ★ 157.7K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.03 | $1.87 |
| 52 Week High | $16.30 | $6.93 |
| Indicator | NYC | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 72.74 |
| Support Level | $7.87 | $2.16 |
| Resistance Level | $10.29 | $6.93 |
| Average True Range (ATR) | 0.74 | 0.65 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 17.56 | 81.29 |
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.